European Organisation for Research and Treatment of Cancer

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 12 Aug 2014
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

50,000€

Financial year: Jan 2013 - Jan 2014

Lobbyists (Full time equivalent)

None declared

Lobbyists with EP accreditation

0

High-level Commission meetings

8

Lobbying Costs over the years

  • Info

    European Organisation for Research and Treatment of Cancer   (EORTC)

    EU Transparency Register

    70539554035-46 First registered on 20 Aug 2010

    Goals / Remit

    Created in 1962, the European Organisation for Research and Treatment of Cancer (EORTC) is a non-profit international cancer research organisation under Belgian Law. The EORTC is recognised as scientific research institution and as non-profit clinical trial sponsor by the Belgian State. The EORTC mission is to improve the standard of cancer treatment in Europe through the development of innovative new drugs and to test more effective therapeutic strategies using commercially available drugs, surgery, or radiotherapy. The EORTC has the aim to facilitate the passage of experimental discoveries into state-of-the-art treatment by keeping to a minimum the time lapse between the discovery of new anti-cancer agents and the implementation of their therapeutic benefit for patients with cancer. This is accomplished mainly by conducting international large, multicentre, prospective, randomised, phase III clinical trials.

    EORTC clinical research trials are conducted in a network of over 300 participating institutions located in 32 countries in which more than 2,900 clinicians and scientists collaborate on a voluntary basis. More than 6,000 cancer patients are entered into EORTC multidisciplinary trials each year. Some 35 EORTC trials are permanently open to patient entry. The activities of the EORTC are peer reviewed by the US National Cancer Institute. All EORTC protocols are written and conducted in accordance with international standards for ethics: the declaration of Helsinki, Good Clinical Practice guidelines approved by the International Conference on Harmonization.

    Independent clinical research is the only way to guarantee an objective evaluation and to establish optimal therapeutic strategies on a multidisciplinary base. However, there is no clinical research possible without collaboration with the industry because of the need for access to innovative new drugs and funding, etc. In order to preserve EORTC independence, EORTC studies must comply with the following basic requirements 1) Clinical study protocol must undergo EORTC pee-review procedures. Input of the academics in the design and the control arm. 2) The clinical study database must be under the full control of EORTC 3) Study primary endpoints must be analysed by independent statistician and reviewed by an Independent Data Monitoring Committee 4) Study results must be published in scientific journal 5) the study bio-samples must be under the custodianship of EORTC.

    Located in Brussels, the EORTC Headquarters is a unique facility in Europe. It provides scientific, legal, logistic and administrative support to the clinical and translational research activities of the EORTC cooperative groups (protocol development, data management, statistical analysis, new drugs development, translational research, physical and virtual biobanking, advanced imaging, quality of life, regulatory and ethical affairs management, training, Pharmacovigilance and Quality Assurance). The EORTC Headquarters staff is constituted by 180 highly experienced and trained professionals. Since 1991, the EORTC Fellowship Program has allowed more than 100 medical doctors, statisticians and health scientists from all over the world to do research project at the EORTC. The EORTC is offering a wide range of training for clinical research professionals ranging from GCP to clinical research methodology.

    Main EU files targeted

    Address

    Head Office
    avenue Mounier
    Brussels 1200
    BELGIUM
  • People

    Total lobbyists declared

    None declared

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    None declared

    Person with legal responsibility

    Mr Stephane Lejeune (EU Programme Coordinator)

  • Categories

    Category

    III - Non-governmental organisations

    Subcategory

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    None declared

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2013 - Jan 2014

    Lobbying costs for closed financial year

    50,000€

    Other financial info

    The EORTC is funded through several sources including the EORTC Charitable Trust providing a core grant which is mainly supported by numerous national cancer leagues.

    Since 1972, the US National Cancer Institute (NCI) has provided support to EORTC Headquarters, and with this support a close scientific collaboration has been maintained to promote transatlantic research projects.

    Core grants from the Fonds Cancer, FOCA (BE) provide support for the EORTC Headquarters staff. EORTC Headquarters also receives grants allocated by BELSPO (the Belgian Federal Science Policy Office) and by the Belgian National Lottery.

    Funding for the Fellowship Programme is provided by the EORTC Charitable Trust, Fonds Cancer, FOCA (BE), the Koningin Wilhelmina Fund, KWF (NL), and several leagues including La Ligue Nationale contre le Cancer (FR) and the Vlaamse Liga tegen Kanker, VLK (BE).

    In addition, grants for EORTC research projects are received from the European Commission under the 6th and the 7th Framework Programmes.

    The EORTC has received support for bio-banking in a prostate cancer clinical trial from the Institute for the encouragement of Institut d'encouragement de la Recherche Scientifique et de l'Innovation de Bruxelles (IRSIB).

    Clinical studies evaluating new drugs for potential registration or testing innovative therapeutic agents, including some educational projects, are conducted in cooperation with pharmaceutical industry partners in strict compliance with EORTC criteria for independence. Pharmaceutical industry sponsorship is also provided in the form of “unrestricted grants” for EORTC conferences.

    The finances of the EORTC include all accounts from the EORTC Headquarters as well as all EORTC Groups and Task Forces. These accounts are consolidated as required under Belgian Law. The EORTC accounts are audited by Ernst & Young.

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    None declared

    Communication activities

    None declared

    Other activities

    None declared

  • Meetings

    Meetings

    8 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

Download this datacard